CYP19A1 and obesity due to melanocortin 4 receptor deficiency: While improving insulin sensitivity is likely to contribute to the decreased breast cancer risk, another important function of metformin in the context of obesity-associated breast cancer is its ability to inhibit aromatase expression in breast ASCs (160, 161).